Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.

Human

OVCAR-3 cells at 1×10^5 cells/well can bind Ubamatamab. The EC50 is 0.421 nM.
huCD3e-Jurkat cells at 1×10^5 cells/well can bind Ubamatamab. The EC50 is 15.06 nM.

Monoclonal

Unconjugated